CD274 and non-small cell lung carcinoma: In this study, atezolizumab was used as an adjuvant drug for the treatment of patients with early NSCLC after postoperative platinum-based chemotherapy (PD-L1 TC ≥ 1% II-IIIA group, all-stage II-IIIA group, ITT group), producing 3.81 QALYs.